Assessment point | Laboratory tests |
Baseline* |
|
Week 4 |
|
Week 12 |
|
Week 24 |
|
Week 48 |
|
Week 12 post-treatment |
|
Week 24 post-treatment |
|
Week 48 post-treatment |
|
CBC: complete blood count; INR: international normalized ratio; TSH: thyroid-stimulating hormone; HDV: hepatitis D virus; HBV: hepatitis B virus; HBeAg: hepatitis B e antigen; anti-HBe: hepatitis B e antibody; HBsAg: hepatitis B surface antigen; ALT: alanine aminotransferase; AST: aspartate aminotransferase.
* Prior to initiating therapy, noninvasive test for liver stiffness or a liver biopsy should be performed to assess for the presence of fibrosis and cirrhosis. In persons with advanced fibrosis or cirrhosis, liver ultrasound should be repeated at week 24 and every 6 months thereafter to evaluate for hepatocellular carcinoma. Elastography may be repeated every 2-3 years to assess for progression/regression.
¶ Hepatic panel includes: ALT, AST, albumin, bilirubin, and alkaline phosphatase.
Δ Only for patients who are HBeAg-positive at baseline.
◊ Quantitative HBsAg should be performed, if available. Quantitative HBsAg should be performed at baseline, week 24 and 48 of treatment, and week 48 post-treatment. If only qualitative HBsAg testing is available, it should be performed at baseline and then repeated at week 48 of treatment and week 48 post-treatment if HBV DNA becomes undetectable.
§ Only for persons of childbearing potential.
¥ This can be used to assess utility of continued therapy.Do you want to add Medilib to your home screen?